1. Home
  2. CSTL vs PRCH Comparison

CSTL vs PRCH Comparison

Compare CSTL & PRCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CSTL
  • PRCH
  • Stock Information
  • Founded
  • CSTL 2007
  • PRCH 2012
  • Country
  • CSTL United States
  • PRCH United States
  • Employees
  • CSTL N/A
  • PRCH N/A
  • Industry
  • CSTL Medical Specialities
  • PRCH Computer Software: Prepackaged Software
  • Sector
  • CSTL Health Care
  • PRCH Technology
  • Exchange
  • CSTL Nasdaq
  • PRCH Nasdaq
  • Market Cap
  • CSTL 561.9M
  • PRCH 656.3M
  • IPO Year
  • CSTL 2019
  • PRCH N/A
  • Fundamental
  • Price
  • CSTL $16.53
  • PRCH $13.19
  • Analyst Decision
  • CSTL Strong Buy
  • PRCH Strong Buy
  • Analyst Count
  • CSTL 6
  • PRCH 8
  • Target Price
  • CSTL $37.67
  • PRCH $10.28
  • AVG Volume (30 Days)
  • CSTL 396.8K
  • PRCH 2.1M
  • Earning Date
  • CSTL 08-04-2025
  • PRCH 08-05-2025
  • Dividend Yield
  • CSTL N/A
  • PRCH N/A
  • EPS Growth
  • CSTL N/A
  • PRCH N/A
  • EPS
  • CSTL N/A
  • PRCH N/A
  • Revenue
  • CSTL $347,083,000.00
  • PRCH $427,150,000.00
  • Revenue This Year
  • CSTL N/A
  • PRCH $2.49
  • Revenue Next Year
  • CSTL $1.36
  • PRCH $14.01
  • P/E Ratio
  • CSTL N/A
  • PRCH N/A
  • Revenue Growth
  • CSTL 38.43
  • PRCH N/A
  • 52 Week Low
  • CSTL $15.45
  • PRCH $1.05
  • 52 Week High
  • CSTL $35.84
  • PRCH $13.62
  • Technical
  • Relative Strength Index (RSI)
  • CSTL 34.83
  • PRCH 65.54
  • Support Level
  • CSTL $19.29
  • PRCH $11.74
  • Resistance Level
  • CSTL $20.26
  • PRCH $13.59
  • Average True Range (ATR)
  • CSTL 0.70
  • PRCH 0.74
  • MACD
  • CSTL -0.35
  • PRCH -0.01
  • Stochastic Oscillator
  • CSTL 4.44
  • PRCH 88.10

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has two reportable segments: The vertical Software segment provides software and services to home services companies. The Vertical Software segment software and services provide inspection, mortgage, and title companies on a subscription and transactional basis, several key businesses, including inspection software and services, title insurance software, mortgage software, moving services, mover and homeowner marketing, and measurement software for roofers. The insurance segment provides consumers with insurance and warranty products to protect their homes, earning revenue through premiums collected on policies, policy fees, and commissions. Majority revenue is from Insurance segment.

Share on Social Networks: